Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity

肝脏靶向二氢喹嗪酮 (DHQ) 分子作为乙型肝炎病毒抗病毒药物,毒性降低

基本信息

  • 批准号:
    10593566
  • 负责人:
  • 金额:
    $ 24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-22 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Hepatitis B virus chronically infects 258 million people worldwide and causes 880 thousand deaths annually due to cirrhosis, hepatocellular carcinoma (HCC) and liver failure. The current standard of care medications, including pegylated interferon alpha that regulates host antiviral immune response and nucleos(t)ide analogues that inhibit viral DNA polymerase, can potently suppress viral replication, but fail to induce the loss of HBV surface antigen (HBsAg), an indication of successful immune control or the functional cure of chronic hepatitis B, in the vast majority of the treated patients. Therefore, the development of novel antivirals with a new mechanism that can activate the host antiviral immune response is required to achieve the functional cure of chronic hepatitis B (CHB). A dihydroquinolizinone (DHQ) RG-7834, a small molecule discovered by Roche, can rapidly reduce hepatitis B virus (HBV) RNA levels, and hence almost all viral gene products, including HBsAg. This represents an entirely new chemotype of HBV antivirals and a new approach for CHB control. However, the observation of neurotoxicity in RG-7834 prohibits its systemic use for the management of CHB. We hypothesize that this side effect can be minimized or eliminated by producing liver selective and CNS refractory DHQ antivirals. In support of this hypothesis, we have recently designed and synthesized a novel series of bis-carboxylic acid based DHQ derivatives that are shown, for the first time in this series, to have organic anion transporting polypeptide (OATP) substrate properties, which facilitates selective distribution of the compounds to the therapeutic site of action (liver), relative to the blood stream. This effort led to the discovery of an early lead, called DHQ-65042, which is potent in both biochemical and cellular assays (EC50 = 23 nM in HepG2.2.15 cell line), while demonstrating considerable safety improvement potential in comparison to RG-7834, such as low blood-brain barrier (BBB) penetration (in vitro assay) and high in vivo liver selectivity over plasma (liver/plasma ratio is 37.8 in a mouse PK study). This novel series of liver targeting DHQs are promising for improving safety profiles through limited distribution to the blood stream, the brain, and other body tissues, though the exposure of DHQ-65042 in the liver from the oral route of a pharmacokinetic (PK) study is moderate. In this R21 proposal, to validate the feasibility of developing novel liver targeting DHQ derivatives as hepatitis B virus surface antigen reducers with practical value, we will perform lead optimization to improve the liver exposure to an efficacious level with low exposure in plasma maintained, and identify a balance window between hepatoselectivity and GI/ liver absorption of new leads through the works proposed in three aims. Successful completion of this project will allow us to develop a new generation of DHQs that are selectively delivered to livers with concentrations sufficient enough to significantly reduce HBsAg and have better safety profiles, and to provide a new lead ready for in vivo toxicity and efficacy studies.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yanming Du其他文献

Yanming Du的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yanming Du', 18)}}的其他基金

Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection
用于治疗和预防甲型肝炎病毒 (HAV) 感染的肝选择性二氢喹嗪酮 (HS-DHQ) 分子
  • 批准号:
    10698516
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction
开发具有更好安全性的肝选择性乙型肝炎治疗二氢喹嗪酮 (DHQ) 分子,可有效降低 HBsAg
  • 批准号:
    10384184
  • 财政年份:
    2022
  • 资助金额:
    $ 24万
  • 项目类别:
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors
乙型肝炎病毒核衣壳组装抑制剂的治疗效果评估
  • 批准号:
    9031576
  • 财政年份:
    2014
  • 资助金额:
    $ 24万
  • 项目类别:
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors
乙型肝炎病毒核衣壳组装抑制剂的治疗效果评估
  • 批准号:
    8850811
  • 财政年份:
    2014
  • 资助金额:
    $ 24万
  • 项目类别:
Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitors
乙型肝炎病毒核衣壳组装抑制剂的治疗效果评估
  • 批准号:
    8766392
  • 财政年份:
    2014
  • 资助金额:
    $ 24万
  • 项目类别:
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors
乙型肝炎病毒核衣壳组装抑制剂的治疗效果评估
  • 批准号:
    9282559
  • 财政年份:
    2014
  • 资助金额:
    $ 24万
  • 项目类别:
Evaluation of therapeutic benefits of HBV nucleocapsid assembly inhibitors
乙型肝炎病毒核衣壳组装抑制剂的治疗效果评估
  • 批准号:
    9069416
  • 财政年份:
    2014
  • 资助金额:
    $ 24万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了